# Role and mechanism of mesenchymal stem cells in endometrial receptivity remodeling

**Authors:** Wang Zhao-Di, Liu Xian-Bao, Lv Liang-Zhen, Li Lu-Hao, Ren Jia-Jie, Zhu Hui, Jiang Bei, Chang Zhuo

PMC · DOI: 10.3389/fcell.2026.1724597 · Frontiers in Cell and Developmental Biology · 2026-03-12

## TL;DR

This paper reviews how mesenchymal stem cells can improve endometrial receptivity and help with infertility by regenerating the uterine lining.

## Contribution

The paper provides a comprehensive overview of MSC mechanisms and clinical evidence in endometrial regeneration.

## Key findings

- MSCs enhance endometrial receptivity through differentiation, angiogenesis, immunomodulation, and extracellular matrix remodeling.
- Umbilical cord-derived MSCs increased endometrial thickness and improved pregnancy rates in a clinical trial.
- Engineered MSC-derived exosomes and biomaterial combinations are promising future directions.

## Abstract

Endometrial receptivity (ER) is a pivotal determinant of successful embryo implantation, and its dysfunction is a major cause of infertility and recurrent implantation failure. Mesenchymal stem cells (MSCs) have emerged as a promising therapeutic strategy due to their multipotency, self-renewal capacity, and potent paracrine activity. This review elucidates the multifaceted mechanisms through which MSCs enhance ER, including direct differentiation into endometrial cells, promotion of angiogenesis via secretion of factors like VEGF, immunomodulation by inducing Treg cells and M2 macrophages, and remodeling of the extracellular matrix. Crucially, we highlight emerging clinical evidence; for instance, in a recent clinical trial, intrauterine infusion of umbilical cord-derived MSCs in women with intrauterine adhesions significantly increased endometrial thickness from a mean of 4.2 ± 0.5 mm to 6.8 ± 0.7 mm and improved the clinical pregnancy rate to 38.5%. Furthermore, we discuss ongoing clinical trials and future directions, such as the development of engineered MSC-derived exosomes and biomaterial-scaffold combinations. Despite challenges in standardization and long-term safety, MSC-based therapy represents a novel and potent approach for regenerating dysfunctional endometrium, offering new hope for refractory infertility.

## Linked entities

- **Proteins:** VEGFA (vascular endothelial growth factor A)
- **Diseases:** intrauterine adhesions (MONDO:0015299)

## Full-text entities

- **Genes:** VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}
- **Diseases:** infertility (MESH:D007246), intrauterine adhesions (MESH:D000267)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13017818/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13017818/full.md

## References

94 references — full list in the complete paper: https://tomesphere.com/paper/PMC13017818/full.md

---
Source: https://tomesphere.com/paper/PMC13017818